Bristol Myers Squibb's cost-cutting initiative will lead to additional layoffs in Lawrenceville, NJ, the company revealed ...

The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director ...

Merck is ending Phase 3 trial of Winrevair (sotatercept) early due to positive interim results in treating pulmonary arterial ...

Is this the end for Cassava Sciences? After a problematic development path riddled with allegations of misleading investors, ...

Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...

Gilead acquires HTI T-cell immunogen HIV vaccines from Barcelona's Aelix Therapeutics for an undisclosed amount. The vaccines ...

Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by ...

As the federal drug discount program known as 340B has seen rapid growth in recent years, Minnesota's Department of Health is looking to shine a light on where that growth is occurring.The first year ...

After recently discontinuing R&D for Truqap in triple-negative breast cancer, AstraZeneca has some good news on its kinase ...

Replimune announces $125M offering after FDA submission for RP1; Otsuka partners with Ionis on ALS drug ulefnersen; Kanglin Biotechnology raises $20M; Seelos files bankruptcy; Orbus reports positive ...

Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street ...

Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of ...